IP Library Granted Patent US 8,669,346
Granted Patent B2
US 8,669,346 · App. 13/195,665 · Granted Mar 11, 2014

Bone marrow targeting peptides

Inventors: James E. Dennis (Cleveland Heights, OH); Thomas Kean (Seattle, WA)
Assignee: Case Western Reserve University
C07K7/06C07K7/00C12N5/06C12N5/0647C12N5/0672
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,669,346
App. No.
13/195,665
Granted
Mar 11, 2014
Kind
B2
Abstract

A peptide for targeting bone marrow consists of about 5 to about 25 amino acids and includes an amino acid sequence that targets the peptide to bone marrow.

Claims (9)

1. A peptide for targeting bone marrow, the peptide consisting of an amino acid sequence of RKVVVGS (SEQ ID NO:4).

2. A composition for targeting bone marrow, the composition comprising a peptide consisting an amino acid sequence of RKVVVGS (SEQ ID NO:4).

3. The composition of claim 2 , further comprising a cell, the peptide targeting the cell to bone marrow when the composition is administered to a subject.

4. The composition of claim 3 , wherein the cell comprises a progenitor cell selected from the group consisting of a totipotent stem cell, pluripotent stem cell, multipotent stem cell, mesenchymal stem cell, hematopoietic stem cell, embryonic stem cell, embryonic germ cell, neural crest stem cell, and endothelial progenitor cell.

5. The composition of claim 3 , wherein the cell comprises an umbilical cord blood cell.

6. A composition for bone marrow transplantation, the composition comprising:

an umbilical cord blood cell; and

a peptide linked to the umbilical cord blood cell, the peptide targeting the umbilical cord blood cell to bone marrow when the composition is administered to a subject, the peptide consisting of an amino acid sequence of RKVVVGS (SEQ ID NO:4).

7. The composition of claim 6 , wherein the umbilical cord blood cell comprises at least one of a CD34+ progenitor cell, a CD133+ progenitor cell, an endothelial progenitor cell, a hematopoietic stem cell, and/or a hemangioblast.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 8, 2016
From: CASE WESTERN RESERVE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 038906/0231 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2011
From: DENNIS, JAMES E.; KEAN, THOMAS
To: CASE WESTERN RESERVE UNIVERSITY
Reel/Frame 026979/0587 →
Continuity (2)
Provisional Application 61369236 · Jul 30, 2010
Related Publication 20120028350A1 · Feb 2, 2012